The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis

Multiple Sclerosis

Volumn 15, Issue 5, 2009, Pages 601-605

  Koch Henriksen, N ^a,b   Sorensen, P S ^b   Bendtzen, K ^b   Flachs, E M ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Interferon beta; Interferon beta antibodies; Multiple sclerosis; Neutralizing antibodies; Therapy; Treatment effect

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; REBIF22; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL OBSERVATION; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; RELAPSE;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ANTIBODY SPECIFICITY; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERFERON-BETA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; REGISTRIES; YOUNG ADULT;

EID: 65349183493     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508101946     Document Type: Article

References (19)

1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group [see comments]. Neurology 1993; 43: 655-661.
2. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/ MRI Analysis Group [see comments]. Neurology 1996; 47: 889-894.
3. Sorensen PS, Ross C, Clemmesen KM. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-1191.
4. PRISMS-4. Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628-1636.
5. Francis GS, Rice GP, Alsop JC. Interferon beta-1a in MS: Results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48-55.
6. Kappos L, Clanet M, Sandberg-Wollheim M. Neutralizing antibodies and efficacy of interferon beta-1a: A 4-year controlled study. Neurology 2005; 65: 40-47.
7. Goodin DS, Hurwitz B, Noronha A. Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 2007;35: 173-187.
8. Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 2000; 48: 95-100.
9. Sominanda A, Hillert J, Fogdell-Hahn A. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent. J Neurol Neurosurg Psychiatry 2008; 79: 57-62.
10. Sominanda A, Rot U, Suoniemi M, Deisenhammer F, Hillert J, Fogdell-Hahn A. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 2007; 13: 208-214.
11. Gibbs E, Oger J. The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients. J Neuroimmunol 2007; 190: 146-150.
12. Koch-Henriksen N, Sorensen PS; The Danish Multiple Sclerosis Group. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. Mult Scler 2000; 6: 172-175.
13. Sorensen PS Koch-Henriksen N, Ross C, Clemmesen KM Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33-39.
14. Schumacher GA, Beebe G, Kibler RF. Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 1965; 122: 552-568.
15. Bendtzen K. Anti-IFN BAb and NAb antibodies: A minireview. Neurology 2003; 61: S6-S10.
16. Hesse D, Sorensen PS. Using measurements of neutralizing antibodies: The challenge of IFN-beta therapy. Eur J Neurol 2007; 14: 850-859.
17. Sorensen PS, Tscherning T, Mathiesen HK. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology 2006; 67: 1681-1683.
18. Gneiss C, Tripp P, Reichartseder F. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult Scler 2006; 12: 731-737.
19. Sorensen, PS, Koch-Henriksen, N, Bendtzen, K. Is treatment effect of IFN-beta restored after disappearance of neutralizing antibodies? Mult Scler 2008; 14: 837-842.